

ArcticZymes Technologies executes contract with consortium for Advanced therapies enzyme project funded by The Research Council of Norway

Tromsø, Norway, June 17, 2024 - ArcticZymes Technologies ASA (OSE: AZT) has today executed a contract with The Research Council of Norway, securing up to 11.8 MNOK for a collaborative project aimed at supporting the advanced therapy biomanufacturing sector.

This follows a previously announced research grant awarded by the Norwegian Research Council. The agreements with the Norwegian Research Council and the project partners, the University of Tromsø - The Arctic University of Norway, and SINTEF Industri have now been finalized, marking the project's commencement. The project has been named AdEPT – Advancing Enzymes for Precision Therapeutics and will run from 2024 through 2027.

In recent years, ArcticZymes Technologies has successfully provided enzymes for manufacturing viral vectors used in cell and gene therapy, as well as vaccines. Viral vectors and nucleic acids like RNA and DNA are increasingly utilized in advanced therapy medicinal products. Enzymes play a crucial role in the manufacturing, analytics, and quality control of these therapeutic RNAs and DNAs. However, significant technical challenges remain, including development costs, commercial scale manufacturing, and sufficient quality for therapeutic use. The project, AdEPT, aims to address these challenges by developing novel enzyme solutions for the manufacturing and analysis of therapeutic RNA.

CEO Michael B. Akoh stated: *“I am pleased to see that we are executing on our strategy to build a unique portfolio of enzymes within the advanced therapies biomanufacturing segment. The collaboration with the University of Tromsø and SINTEF Industri, and funding from The Research Council of Norway provides an excellent foundation. I look forward to following the project's progress over the coming years and witnessing the emergence of new prototypes that can help realize the potential of the many new therapeutic modalities currently in development.”*

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world.

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh

CFO, Børge Sørvoll

Tel: +46 (0) 70 262 37 15

Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions

to enhance quality of life and create a more sustainable healthy world. For more information, please visit the website: www.arcticzymes.com